Findings showed nivolumab/relatlimab did not significantly improve recurrence-free survival compared with nivolumab monotherapy. A phase 3 trial evaluating nivolumab and relatlimab-rmbw (Opdualag ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback